I saw the directors buying up, and I bought in too. I saw the signs. so did the shorts, who all pretty much evaporated. relatively speaking. I agree the signs were everywhere.
tbh I haven't looked much at CLBP. but what I've found with almost everything else is that MSB is VERY selective about its cohort participants. oddly specific. too specific imho. so specific the effects may not actually be generalisable.
japan learned this the hard way.
if the CLBP trials are genuinely heterogeneous in their recruitment, then yeah .... maybe. but I have a feeling, If the data is available, that there might be some very specific recruiting going on once again. which, is not to say the treatment doesn't work to some extent. just probably not as often or as much as demonstrated in the trials.
but all that aside. why does all this matter? because it's about commercial viability as a business. hence why I keep banging on about rux.
I really don't think that last CR was in fact the last CR. this company has business problems. potentially science problems as well. but business problems are the bigger one at the minute.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)